Triple
T22693064
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | RAINBOWFISH |
E561099
|
entity |
| Predicate | studiesDrug |
P65948
|
FINISHED |
| Object | risdiplam (Evrysdi) |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: risdiplam (Evrysdi) | Statement: [RAINBOWFISH, studiesDrug, risdiplam (Evrysdi)]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: risdiplam (Evrysdi) Context triple: [RAINBOWFISH, studiesDrug, risdiplam (Evrysdi)]
-
A.
Evrysdi
chosen
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Soliris
Soliris is a monoclonal antibody drug used to treat rare, life-threatening blood and autoimmune disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
-
C.
Ultomiris
Ultomiris is a long-acting monoclonal antibody therapy used to treat rare complement-mediated blood disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
AMVUTTRA (vutrisiran)
AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789c6ae481908975b7d27e7624ac |
completed | April 29, 2026, 3:18 a.m. |
Created at: April 17, 2026, 3:13 p.m.